Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement
Abstract
Diffuse large B-cell lymphoma (DLBCL), the most common type of human immunodeficiency virus (HIV)-related lymphoma, is associated with a high risk of central nervous system (CNS) involvement. Studies have shown that CD20×CD3 bispecific antibodies have significant therapeutic efficacy in refractory B-cell lymphoma. Preliminary reports indicate that the monoclonal antibody glofitamab can penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients by activating T lymphocytes. This report presents preliminary clinical evidence on the use of glofitamab in HIV-positive patients with secondary CNS lymphoma.
Fields of Study & Subjects
CNS Lymphoma Diagnosis and Treatment
Viral-associated cancers and disorders
HIV Research and Treatment
Publication details
- Journal / source
- Frontiers in Oncology
- Volume
- 15
- Pages
- 1699475–1699475
- Publication date
- 17 February 2026
- Language
- EN